Pluri Inc (PLUR)

Pluri Inc. is a biotechnology company focused on research, development, and manufacturing of cell-based products, cell therapeutics, and related technologies. Its pipeline includes placenta-derived cell therapy candidates aimed at inflammatory conditions, muscle injuries, and hematologic disorders, along with an immunotherapy platform. Key programs include PLX-PAD, which is being studied for indications such as acute muscle injury after hip fracture, acute respiratory distress syndrome related to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia, and PLX-R18, a placenta-derived cell therapy under development for hematopoietic complications and in Phase I testing for hematopoietic cell transplantation. The company also works on an allogeneic MAIT cell therapy platform, offers cell manufacturing services and cell-based coffee, and develops cultivated meat products. Its activities span regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. Pluri has a collaboration with Bar-Ilan University on cancer immunotherapy for solid tumors, and it is based in Haifa, Israel.

Jump directly to the stock analysis sections supported by the latest available data.